

	Total, no. (%) (n=87)	RDI		P value ^a
		<85%, no. (%) (n=40)	≥85%, no. (%) (n=47)	
Ethnicity				0.035
Chinese	69 (79.3)	32 (80.0)	37 (78.7)	
Malay	9 (10.3)	7 (17.5)	2 (4.3)	
Indian	4 (4.6)	1 (2.5)	3 (6.4)	
Others	5 (5.7)	0 (0.0)	5 (10.6)	
Age at the first dose of T-Dxd, years				0.126 ^b
Median (range)	59.0 (32.0–91.0)	60.0 (35.0–83.0)	58.0 (32.0–91.0)	
Estrogen receptor status				0.150
Positive	59 (67.8)	24 (60.0)	35 (74.5)	
Negative	28 (32.2)	16 (40.0)	12 (25.5)	
Progesterone receptor status				0.302
Positive	40 (46.0)	16 (40.0)	24 (51.1)	
Negative	47 (54.0)	24 (60.0)	23 (48.9)	
HER2 status				0.632
IHC 1+	10 (11.5)	6 (15.0)	4 (8.5)	
IHC 2+	37 (42.5)	16 (40.0)	21 (44.7)	
FISH				0.103
Positive	28 (75.7)	10 (62.5)	18 (85.7)	
Negative	9 (24.3)	6 (37.5)	3 (14.3)	
IHC 3+	40 (46.0)	18 (45.0)	22 (46.8)	
CNS metastasis				0.327
Yes	24 (27.6)	9 (22.5)	15 (31.9)	
No	63 (72.4)	31 (77.5)	32 (68.1)	
Lines of treatment (for metastatic disease)				0.573 ^b
Median (IQR)	4 (3–7)	5 (3–8)	4 (3–6)	
Range	1–15	1–14	1–15	
Reduction in RDI by >10% after first dose				0.008
Yes	46 (52.9)	15 (37.5)	31 (66.0)	
No	41 (47.1)	25 (62.5)	16 (34.0)	

CNS: central nervous system; FISH: fluorescent in situ hybridisation; HER2: human epidermal growth receptor 2; IHC: immunohistochemistry; IQR: interquartile range; RDI: relative dose intensity; T-Dxd: trastuzumab deruxtecan

^a Based on chi-square test, unless otherwise specified.

^b Based on Mann-Whiney U test.